Literature DB >> 6606679

Specificity of in vitro anti-influenza virus antibody production by human lymphocytes: analysis of original antigenic sin by limiting dilution cultures.

R Yarchoan, D L Nelson.   

Abstract

The fine specificity of the antibody produced in in vitro cultures of human lymphocytes stimulated with influenza virus was investigated. The antibody was specific for the stimulating type of virus in that cultures stimulated with type B influenza virus made little or no antibody to type A viruses and vice versa. There was a degree of cross-reactivity among the type A viruses, however, both within and between subtypes. In general, more antibody was made to the stimulating strain of virus than to heterologous strains, with the exception that cultures of mononuclear cells from four of five donors stimulated with A/Bangkok/79 (H3N2) made more antibody to A/Aichi/68 (H3N2) than to the stimulating virus, likely reflecting the original antigenic exposure of these donors. The specificity of this in vitro response was further investigated by using monospecific antibodies produced in limiting dilution cultures. Approximately 30% of the antiviral antibodies produced in these cultures bound to purified hemagglutinin, but only 7% bound to purified matrix protein. When antibodies stimulated with A/Bangkok/79 were analyzed for their binding to other H3N2 viruses, a variety of reactivity patterns was observed. Some antibodies were specific for A/Bangkok/79 and some bound to common determinants found on a number of H3N2 viruses. In addition, a number of antibodies were observed that did not bind to A/Bangkok/79 but did bind to earlier H3N2 viruses, demonstrating an extreme form of "original antigenic sin." A similar variety of reactivity patterns was observed when antibodies were tested for binding to heterotypic type A viruses or hemagglutinins. The results of the present experiments demonstrate that the fine specificity of an in vitro human antibody response can be analyzed by using limiting dilution cultures, and suggest that the fine specificity of the antibody response of an individual to a strain of influenza virus is affected by previous antigenic exposure of that individual.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6606679

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  7 in total

1.  Limiting dilution analysis of specific in vitro anti-herpes simplex virus antibody production by human lymphocytes.

Authors:  M Yasukawa; Y Kobayashi
Journal:  Clin Exp Immunol       Date:  1987-04       Impact factor: 4.330

2.  Demonstration of zoster virus antibodies in cerebrospinal fluid cells.

Authors:  W Beuche; R S Thomas; K Felgenhauer
Journal:  J Neurol       Date:  1989-01       Impact factor: 4.849

3.  Development of subtype-specific and heterosubtypic antibodies to the influenza A virus hemagglutinin after primary infection in children.

Authors:  D B Burlington; P F Wright; K L van Wyke; M A Phelan; R E Mayner; B R Murphy
Journal:  J Clin Microbiol       Date:  1985-05       Impact factor: 5.948

4.  Vaccination with inactivated influenza A virus during pregnancy protects neonatal mice against lethal challenge by influenza A viruses representing three subtypes.

Authors:  I N Mbawuike; H R Six; T R Cate; R B Couch
Journal:  J Virol       Date:  1990-03       Impact factor: 5.103

5.  Original antigenic sin and pandemic (H1N1) 2009.

Authors:  Amesh A Adalja; D A Henderson
Journal:  Emerg Infect Dis       Date:  2010-06       Impact factor: 6.883

6.  Characterization of immune responses induced by immunization with the HA DNA vaccines of two antigenically distinctive H5N1 HPAIV isolates.

Authors:  Yulong Gao; Zhiyuan Wen; Ke Dong; Gongxun Zhong; Xiaomei Wang; Zhigao Bu; Hualan Chen; Ling Ye; Chinglai Yang
Journal:  PLoS One       Date:  2012-07-31       Impact factor: 3.240

7.  Lipopeptide vaccines illustrate the potential role of subtype-crossreactive T cells in the control of highly virulent influenza.

Authors:  Wy Ching Ng; Brad Gilbertson; Bock Lim; Weiguang Zeng; David C Jackson; Lorena E Brown
Journal:  Influenza Other Respir Viruses       Date:  2009-07       Impact factor: 4.380

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.